apc-100
Small moleculeexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2011 (NCT01436214)
Timeline
2010s
- Jan 1, 2011
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Androgen ReceptorANTAGONIST
AR antagonist
Vitamin E derivate
Chemistry & pharmacology
Loading structure…
SMILES
Cc1c(C)c2c(c(C)c1O)CCC(C)(C)O2- Mol. weight
- 220.31 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL37676 ↗
Also known as
- apc-100
- apc-100
- apc-100
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01436214 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2011 | Adamis Pharmaceuticals Corporation, University of Wisconsin, Wayne State University |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Adamis Pharmaceuticals Corporation | For profit | 1 | 1 | 1 | 2011 |
| University of Wisconsin | Academic/Hospital | 1 | 0 | 1 | 2011 |
| Wayne State University | Academic/Hospital | 1 | 0 | 1 | 2011 |
3 organizations
Page 1 / 1